VF
ACRS icon

Virtu Financial’s Aclaris Therapeutics ACRS Stock Holding History

Virtu Financial’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,622
Closed -$13K – 1311
2024
Q2 		$13K Buy
+11,622
New +$13.7K ﹤0.01% 1092
2021
Q1 		– Sell
-21,811
Closed -$141K – 1547
2020
Q4 		$141K Buy
+21,811
New +$92K 0.02% 965
2020
Q3 		– Sell
-37,447
Closed -$61K – 992
2020
Q2 		$61K Buy
+37,447
New +$50.2K 0.01% 978
2019
Q4 		$73K Sell
38,710
-15,471
-29% -$25.6K 0.01% 1142
2019
Q3 		$59K Sell
54,181
-29,358
-35% -$41.6K ﹤0.01% 1169
2019
Q2 		$183K Buy
83,539
+71,781
+610% +$391K 0.01% 1039
2019
Q1 		$70K Buy
+11,758
New +$77.9K ﹤0.01% 1171

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial's ACRS Position: Q3 2024 in Review

Virtu Financial sold out of Aclaris Therapeutics (ACRS) in Q3 2024, closing a stake of 11,622 shares — an estimated $13K sold.

Virtu Financial first reported a position in ACRS in Q1 2019 and held it in 7 quarters. The position peaked at $183K in Q2 2019. 81 funds tracked by Wall St. Rank hold ACRS as of Q3 2024.

  • Virtu Financial reported no remaining Aclaris Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Virtu Financial sold 11,622 Aclaris Therapeutics shares in Q3 2024, an estimated $13K.
  • Virtu Financial first reported a position in Aclaris Therapeutics in Q1 2019 and held it in 7 quarters.
  • Virtu Financial's Aclaris Therapeutics position peaked at $183K in Q2 2019.
  • 81 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2024.

Based on Virtu Financial's 13F filing for Q3 2024, filed 20 Nov 2024.